Stanford researchers have developed synthetic proteins that can rewire cancer cells in a lab dish by co-opting critical disease-associated pathways
Synthetic proteins engineered to recognize overly active biological pathways can kill cancer cells while sparing their healthy peers, according to a study by researchers at the Stanford University School of Medicine.
The customizable approach, which the researchers call RASER, relies on just two proteins: The first is activated in the presence of an “always on” growth signal often found in cancer cells, and the second carries out a researcher-programmed response, such as triggering the expression of genes involved in cell death.
Although the experiments were confined to cells grown in the laboratory, the researchers believe the results could lead to a new type of cancer therapy in which synthetic proteins deliver highly targeted and customizable treatments to sidestep the sometimes devastating side effects of current options.
“We’re effectively rewiring the cancer cells to bring about an outcome of our choosing,” said Michael Lin, MD, PhD, associate professor of neurobiology and of bioengineering. “We’ve always searched for a way to kill cancer cells but not normal cells. Cancer cells arise from faulty signals that allow them to grow inappropriately, so we’ve hacked into cancer cells to redirect these faulty signals to something useful.”
A paper describing the work was published May 2 in Science. Lin is the senior author. Former graduate student Hokyung Chung, PhD, is the lead author.
Signals from receptors
Many cancers rely on a series of signals that originate from proteins called receptors that span the membrane of the cell. These signaling cascades, or pathways, are used by healthy cells to grow in response to external cues, for example during development or recovery from injury. Often, however, these receptor proteins are mutated or overexpressed in cancer cells in ways that render the receptor protein “always on,” providing the cell with constant, unwarranted signals for growth. The researchers focused on two receptors, EGFR and HER2 — members of a family of receptors called the ErbB receptors — that often drive the growth of brain, lung and breast cancers. HER2, for example, is targeted by Herceptin in breast cancer.
Many common anti-cancer drugs, including Herceptin, work by blocking the cascade of signals triggered by receptor activation. Unfortunately, however, these drugs have no way to discriminate between cancerous cells, in which the pathway is always activated, and healthy cells going about their business as usual. That’s where Lin and his team come in.
“We haven’t had a drug that can tell the difference between a pathway signaling normally and one that is abnormally active,” Lin said. “We knew we needed a better strategy, a more rational way of treating cancer. But we’ve not had a way to do it until recently.”
Chung and her colleagues designed a synthetic protein consisting of two natural proteins fused together — one that binds to active ErbB receptors and another that cleaves a specific amino acid sequence. They then engineered a second protein that binds to the inner surface of the cell membrane and contains a customizable “cargo” sequence that can carry out specific actions in the cell. When the first protein binds to an active ErbB receptor, it cuts the second protein and releases the cargo into the interior of the cell.
“When the receptor protein is always on, as it is in cancer cells, the released cargo protein accumulates over time,” Chung said. “Eventually enough accumulates to have an effect on the cell. In this way, the system produces an effect only in cancer cells, and we can convert the always-on state of the receptor into different outcomes through the choice of cargo protein.”
After several rounds of tinkering, the team saw that their RASER system, which stands for “rewiring of aberrant signaling to effector release,” was highly specific for cancer cells dependent on ErbB receptor activity. For their first test they chose to use a protein involved in triggering cell death as the RASER cargo.
Killing only overactive cells
The team compared the RASER system to two therapies currently used for metastatic breast cancer — a chemotherapy regimen and a drug that blocks ErbB activity — on several types of cultured cells: breast and lung cancer cells in which the ErbB pathway was overly active; breast cancer cells in which ErbB activity was normal; and noncancerous breast and lung cell lines.
The researchers found that the traditional chemotherapy regimen of carboplatin and paclitaxel killed all the cells indiscriminately. The effect of the ErbB pathway inhibitor on the viability of the cells varied and did not reliably correlate with ErbB pathway activity levels. Only RASER specifically killed those cells in which the ErbB pathway was overly active while sparing those in which ErbB activity was normal.
We knew we needed a better strategy, a more rational way of treating cancer. But we’ve not had a way to do it until recently.
While much work remains to be done to learn whether RASER is effective in human tumors, the researchers are excited about the possibilities of re-engineering the system to recognize other receptors mutated in cancers and swapping the cargos to achieve different outcomes. Challenges include learning how best to deliver synthetic proteins into tumors and understanding how the immune system might react to RASER. But Lin is optimistic.
“We have so much more information now about cancer genomics, signaling and how cancer cells interact with the immune system,” Lin said. “It’s finally becoming practical to combine this knowledge with synthetic biology approaches to tackle some of these pressing human health problems. RASER is both customizable and generalizable, and it allows us for the first time to selectively target cancer cells while sparing normal signaling pathways.”
The Latest on: Synthetic proteins
via Google News
The Latest on: Synthetic proteins
- Lab-made antibody might block coronavirus infectionon June 24, 2020 at 10:21 am
we think it would work as an injection either once every two weeks or maybe even once a month.” The synthetic protein, MDR504, effectively blocked the SARS-COV-2 virus from attaching to ACE2 in cell ...
- CD Bioparticles: A Trustworthy Provider of All Sorts of PEG Conjugationson June 23, 2020 at 10:54 am
New York, USA - June 23, 2020 - Polyethylene glycol (PEG), a biocompatible, synthetic, hydrophilic polyether compound ... is the covalent conjugation of drug targets such as peptides, proteins, or ...
- Universal mosquito vaccine testedon June 23, 2020 at 9:18 am
A small trial showed that a vaccine designed to provide broad protection against mosquito-borne diseases is safe and causes a strong immune response in healthy volunteers.
- Synthetic materials mimic living creatureson June 22, 2020 at 1:05 pm
Researchers have developed a family of soft materials that imitates living creatures. When hit with light, the film-thin materials come alive -- bending, rotating and even crawling on surfaces.
- Tulane University researchers develop synthetic antibody against COVID-19on June 22, 2020 at 10:25 am
Tulane University researchers say they have developed a synthetic antibody against COVID-19. Scientists working to develop drugs against COVID-19 are focused on interrupting its interaction with ACE2, ...
- MIT Automated Tabletop Fast Protein Synthesis Machine May Accelerate Drug Developmenton June 22, 2020 at 4:16 am
Automated tabletop machine could accelerate the development of novel drugs to treat cancer and other diseases. Many proteins are useful as drugs for disorders such as diabetes, cancer, and arthritis.
- Synthetic peptide could be an effective COVID-19 treatment and SARS-CoV-2 vaccineon June 21, 2020 at 10:48 pm
Ligandal, one of the world’s leading genetic medicine companies, has modeled a synthetic peptide that could be an effective ... and vaccines—and may bolster the efficacy of spike protein vaccines in ...
- Synthetic COVID-19 fuels the race for vaccineon June 18, 2020 at 9:21 pm
In the U.S., Bay Area labs are crafting the virus and its genes — synthetically and safely, tweaked so they’re not infectious.
- Race for a vaccine: Synthetic COVID-19 viruses, built from scratch in the Bay Area, fuel critical researchon June 17, 2020 at 6:00 am
Bay Area labs are crafting custom-ordered genes, viruses and antibodies. Designed, built and shipped to labs around the world, these synthetic creations are accelerating the development of ...
- GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Allianceon June 16, 2020 at 2:46 pm
GlaxoSmithKline got its first taste of synthetically lethal cancer therapies via an acquisition. Now it’s trying for a bigger bite of this emerging drug ...
via Bing News